Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) – Stock analysts at Cantor Fitzgerald raised their FY2017 EPS estimates for shares of Aerie Pharmaceuticals in a research note issued to investors on Thursday. Cantor Fitzgerald analyst E. Piros now anticipates that the company will earn ($2.99) per share for the year, up from their prior estimate of ($3.15). Cantor Fitzgerald currently has a “Overweight” rating and a $62.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aerie Pharmaceuticals’ FY2018 earnings at ($2.10) EPS.

Several other research firms have also recently issued reports on AERI. Stifel Nicolaus restated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, May 26th. Cowen and Company set a $100.00 target price on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 26th. ValuEngine upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Aegis upped their target price on shares of Aerie Pharmaceuticals from $63.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, May 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company’s stock. Aerie Pharmaceuticals currently has an average rating of “Buy” and an average target price of $65.67.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/24/aerie-pharmaceuticals-inc-nasdaqaeri-to-post-fy2017-earnings-of-2-99-per-share-cantor-fitzgerald-forecasts.html.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 57.80 on Monday. The company’s 50-day moving average is $53.86 and its 200-day moving average is $46.51. The stock’s market cap is $1.94 billion. Aerie Pharmaceuticals has a 12-month low of $16.61 and a 12-month high of $59.50.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.02.

Large investors have recently added to or reduced their stakes in the stock. C WorldWide Group Holding A S raised its stake in Aerie Pharmaceuticals by 5.6% in the first quarter. C WorldWide Group Holding A S now owns 76,091 shares of the company’s stock valued at $3,451,000 after buying an additional 4,008 shares during the last quarter. Tocqueville Asset Management L.P. raised its stake in Aerie Pharmaceuticals by 19.8% in the first quarter. Tocqueville Asset Management L.P. now owns 90,900 shares of the company’s stock valued at $4,122,000 after buying an additional 15,000 shares during the last quarter. Wells Fargo & Company MN raised its stake in Aerie Pharmaceuticals by 22.1% in the first quarter. Wells Fargo & Company MN now owns 26,273 shares of the company’s stock valued at $1,191,000 after buying an additional 4,758 shares during the last quarter. First Mercantile Trust Co. raised its stake in Aerie Pharmaceuticals by 29.9% in the first quarter. First Mercantile Trust Co. now owns 7,031 shares of the company’s stock valued at $319,000 after buying an additional 1,620 shares during the last quarter. Finally, Columbus Circle Investors raised its stake in Aerie Pharmaceuticals by 20.8% in the first quarter. Columbus Circle Investors now owns 282,309 shares of the company’s stock valued at $12,803,000 after buying an additional 48,689 shares during the last quarter. 92.01% of the stock is owned by hedge funds and other institutional investors.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the company’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total transaction of $1,119,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.36% of the stock is owned by corporate insiders.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.